Format

Send to

Choose Destination
Oncotarget. 2017 Aug 3;8(48):84579-84594. doi: 10.18632/oncotarget.19961. eCollection 2017 Oct 13.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.

Author information

1
Division of Medical Oncology & Hematology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
2
Division of Gynecologic Cancer, Department of OB/GYN, NYU Langone Laura and Isaac Perlmutter Cancer Center, New York, NY, United States.
3
Division of Gynecologic Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, CA, United States.
4
Reproductive Cancer Genetics Section, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute/NIH, MSC 8000, Bethesda, ML, United States.
5
University of British Columbia & BC Cancer Agency, Division of Gynecologic Oncology, Vancouver, British Columbia, Canada.
6
Department of Gynecology, Obstetrics and Reproductive Sciences, Yale School of Medicine, New Haven, CT, United States.
7
Section of Hematology-Oncology, Department of Medicine, The University of Chicago, Chicago, IL, United States.
8
Department of Obstetrics & Gynecology, Washington University School of Medicine, St. Louis, MO, United States.
9
Medical Sciences Program, Indiana University School of Medicine, Bloomington, IN, United States.
10
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, ML, United States.
11
James Comprehensive Cancer Center and The Department of Obstetrics and Gynecology, Ohio State University, Columbus, OH, United States.
12
Division Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford, CA, United States.
13
Department of Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
14
Department of Pathology, Unit 85, University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.
15
Clinical Investigations Branch of The Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, ML, United States.

Abstract

The incidence and mortality rates from endometrial cancer are increasing. There have been no new drugs approved for the treatment of endometrial cancer in decades. The National Cancer Institute, Gynecologic Cancer Steering Committee identified the integration of molecular and/or histologic stratification into endometrial cancer management as a top strategic priority. Based on this, they convened a group of experts to review the molecular data in this disease. Here we report on the actionable opportunities and therapeutic directions identified for incorporation into future clinical trials.

KEYWORDS:

endometrial cancer; molecular targets

Conflict of interest statement

CONFLICTS OF INTEREST The following authors have no conflicts of interests to disclose: Helen J MacKay, Douglas A Levine, Victoria L Bae-Jump, Jessica N McAlpine, Alexandro Santin, Gini F Fleming, David G Mutch, Kenneth P Nephew, Nicholas Wentzensen, Paul J Goodfellow, Oliver Dorigo, Hans W Nijman, Russell Broaddus and Elise C Kohn.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center